Compassionate Use Trial for Unresectable Melanoma With Ipilimumab

Clinical Trial ID NCT00495066

PubWeight™ 19.75‹?›

🔗 Visit the ClinicalTrials.gov page for NCT00495066

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma. J Clin Oncol 2015 5.49
2 Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol 2013 5.36
3 Sequencing of BRAF inhibitors and ipilimumab in patients with metastatic melanoma: a possible algorithm for clinical use. J Transl Med 2012 1.60
4 Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution. Endocr Relat Cancer 2014 1.32
5 Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody. Sci Transl Med 2014 1.29
6 Increased frequency of ICOS+ CD4 T cells as a pharmacodynamic biomarker for anti-CTLA-4 therapy. Cancer Immunol Res 2013 1.29
7 Clinical activity of ipilimumab for metastatic uveal melanoma: a retrospective review of the Dana-Farber Cancer Institute, Massachusetts General Hospital, Memorial Sloan-Kettering Cancer Center, and University Hospital of Lausanne experience. Cancer 2013 1.22
8 Computational algorithm-driven evaluation of monocytic myeloid-derived suppressor cell frequency for prediction of clinical outcomes. Cancer Immunol Res 2014 1.06
9 Survivorship in Immune Therapy: Assessing Chronic Immune Toxicities, Health Outcomes, and Functional Status among Long-term Ipilimumab Survivors at a Single Referral Center. Cancer Immunol Res 2015 0.86
10 Clinical Development of Immune Checkpoint Inhibitors. Biomed Res Int 2015 0.82
11 Chemokine receptor patterns in lymphocytes mirror metastatic spreading in melanoma. J Clin Invest 2016 0.80
Next 100